MedTrace Logo

Helicobacter Pylori Eradication Treatment in Patients With Duodenal Ulcers

NCT01199536 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 59

Last updated 2013-11-25

No results posted yet for this study

Summary

The Study purpose is to evaluate Helicobacter pylori susceptibility to Clarithromycin and to estimate eradication and healing rates of duodenal ulcer routine eradication therapy at the end of treatment and 52 weeks from the therapy start

Conditions

  • Duodenal Ulcer

Sponsors & Collaborators

Principal Investigators

  • Vladimir T. Ivashkin · Head of Chair of Internal Diseases Propedeutics and Gastroenterology at MMA n/a I.M. Sechenov

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • Russia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01199536 on ClinicalTrials.gov